Use of Apixaban and Rivaroxaban for AF in Patients
with Obesity and a BMI ≥50 kg/m2
O’Kane CP, Avalon JCO, Lacoste JL, Fang W, Bianco CM, Davisson L, and Piechowski KL.
Objectives: To evaluate the effectiveness and safety of apixaban and
rivaroxaban initiated in patients with NVAF and a BMI ≥50 kg/m2
To compare clinical outcomes to a randomly selected cohort of patients with BMIs ranging from 18 to 30 kg/m2
